A study conducted by Stephen et al. at Western Hospital in Scotland examined the effects of levetiracetam (LEV) monotherapy and published the results in a recent issue of Seizure. The study included 228 patients aged 12 to 81 years with epilepsy, of whom 161 (70.6%) had partial epilepsy and 59 (25.9%) had idiopathic generalized epilepsy. The dose of LEV treatment was 250 mg (bid) for the first 2 weeks and subsequently increased to 500 mg (bid). If needed, the dose could be gradually increased from 500 mg to the maximum tolerated or effective dose, and patients were evaluated every 6 to 8 weeks. The results found that 112 patients who remained seizure-free for ≥1 year were on LEV at a mean dose of 1000 mg/d; patients who were on LEV monotherapy at the start were more likely to be seizure-free than those who were first treated with other drugs and then switched to LEV; and patients who were treated with LEV at <5 seizures were more likely to be seizure-free than those who were treated with LEV at ≥5 seizures.